A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

What Was Tested

In this phase 2 trial, researchers set out to test Tirzepatide and Bimagrumab.

Participation in the study will last about 13 months.

It had nine arms (groups): one (experimental), one (experimental), one (experimental), one (experimental) and one (experimental).

Participants will receive bimagrumab subcutaneously (SC) and tirzepatide placebo SC.

Participants will receive bimagrumab SC and tirzepatide placebo SC.

Participants will receive tirzepatide SC and bimagrumab placebo SC.

The registry classes the interventions as drug.

Who Took Part

It was open to people of any sex aged from 18 years up to 75 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Have type 2 diabetes. Have a BMI of ≥27 kilograms per square meter (kg/m2).

The full record lists 3 inclusion and 17 exclusion criteria; among the exclusions: have a prior or planned surgical treatment for obesity,; have type 1 diabetes, latent autoimmune diabetes, or history of ketoacidosis or hyperosmolar state or coma; have poorly controlled hypertension.

How the Study Was Run

It was run as a randomized, parallel-group and double-blind study.

Random assignment meant chance, not the researchers, decided who got Tirzepatide and who got the comparison, which limits bias.

The Tirzepatide group and the comparison group ran side by side rather than switching.

Neither the participants nor the staff measuring them knew who was on Tirzepatide, so expectations could not easily colour the readings.

Those kept unaware of assignments: participant and investigator.

It started in 2025-05-23 with completion listed for 2025-06-10.

It ran at 50 sites in United States (25), Japan (8), Canada (7), China (6) and Argentina (4).

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: Percent Change from Baseline in Body Weight (time frame: Baseline, Week 36).

It also tracked 15 secondary outcomes, for example Percent Change from Baseline in Total Body Fat Mass by Dual-Energy X-Ray Absorptiometry (DXA), Change from Baseline in Hemoglobin A1c (HbA1c), Change from Baseline in Waist Circumference, Change from Baseline in Body Mass Index (BMI), Change from Baseline in Waist-to-Height Ratio (WHtR) and Percent Change from Baseline in Visceral Adipose Tissue (VAT) by Magnetic Resonance Imaging (MRI).

What This Means in Plain Language

Put simply, this is a phase 2, randomized trial of Tirzepatide and Bimagrumab in people.

It was withdrawn before enrolling anyone; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Tirzepatide compound page and the Bimagrumab compound page, all human trials.